Near-Infrared Light Therapy Eases Chemotherapy Nerve Damage in Preclinical Study
808 nm photobiomodulation reduces pain, restores nerve fibers, and protects mitochondria in paclitaxel-induced neuropathy models.
Summary
Chemotherapy-induced peripheral neuropathy (CIPN) causes debilitating pain and sensory loss in cancer patients, with few effective treatments. Researchers tested 808 nm near-infrared photobiomodulation (PBM) in mice and cell models exposed to paclitaxel. Three weeks of PBM treatment reduced mechanical and cold hypersensitivity, restored intraepidermal nerve fiber density, and preserved mitochondrial structure. In cell studies, PBM boosted neuronal survival, cut inflammatory cytokines, lowered oxidative stress, stabilized mitochondrial membrane potential, increased ATP output, and blocked apoptosis via the mitochondrial pathway. The findings position PBM as a promising non-drug option for CIPN management pending clinical trials.
Detailed Summary
Chemotherapy-induced peripheral neuropathy affects up to 80% of patients receiving paclitaxel-based regimens, producing chronic pain, numbness, and tingling that significantly impair quality of life and can force dose reductions. Current pharmacological options—including duloxetine and gabapentin—offer only partial relief, making new therapeutic strategies urgently needed.
This preclinical study from Xi'an Jiaotong University evaluated whether 808 nm near-infrared photobiomodulation could alleviate CIPN. A murine CIPN model was developed using nab-paclitaxel, and animals received three weeks of continuous PBM. In parallel, N2a neuroblastoma cells and normal human astrocytes were exposed to paclitaxel with or without PBM in vitro.
In vivo, PBM significantly reduced mechanical and cold hypersensitivity, restored intraepidermal nerve fiber density, and preserved mitochondrial ultrastructure while lowering oxidative tissue damage. In vitro, PBM enhanced neuronal proliferation, suppressed pro-inflammatory cytokine expression, reduced oxidative stress markers, stabilized mitochondrial membrane potential, increased ATP production, and inhibited paclitaxel-triggered apoptosis through the mitochondrial pathway.
The convergence of anti-inflammatory, antioxidant, and mitochondria-protective effects suggests PBM targets multiple nodes of CIPN pathophysiology simultaneously—a potential advantage over single-target drugs. Because PBM is non-invasive and already approved for some pain indications, translation to cancer care settings is feasible.
Important caveats remain. The study is preclinical, relying on rodent and cell-culture models that may not fully recapitulate human CIPN. Optimal dosing parameters, treatment duration, and long-term safety in immunocompromised cancer patients require dedicated clinical investigation before PBM can be routinely recommended.
Key Findings
- 808 nm PBM over 3 weeks significantly reduced mechanical and cold hypersensitivity in paclitaxel-treated mice.
- PBM restored intraepidermal nerve fiber density and preserved mitochondrial ultrastructure in vivo.
- PBM suppressed pro-inflammatory cytokines and reduced oxidative stress in neuronal and astrocyte cell models.
- Mitochondrial membrane potential stabilized and ATP production increased following PBM treatment in vitro.
- PBM inhibited paclitaxel-induced apoptosis via regulation of the mitochondrial apoptotic pathway.
Methodology
Researchers used a murine nab-paclitaxel CIPN model with three weeks of 808 nm PBM, assessing behavior, nerve fiber density, and mitochondrial ultrastructure in vivo. In vitro experiments on N2a neuroblastoma cells and normal human astrocytes measured viability, cytokines, oxidative stress, mitochondrial function, and apoptosis with and without PBM.
Study Limitations
All data come from rodent and cell-culture models, limiting direct extrapolation to human CIPN. Optimal PBM parameters—wavelength, dose, frequency, and duration—for clinical use remain undefined. Safety and efficacy in immunocompromised cancer patients undergoing active chemotherapy have not been evaluated.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: